{"id":61021,"date":"2025-02-06T04:37:58","date_gmt":"2025-02-06T04:37:58","guid":{"rendered":"https:\/?p=61021"},"modified":"2025-02-06T04:37:58","modified_gmt":"2025-02-06T04:37:58","slug":"novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted","status":"publish","type":"post","link":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/","title":{"rendered":"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted"},"content":{"rendered":"<div class=\"flex-1 overflow-hidden @container\/thread translate-y-[1.5rem] -mt-[1.5rem] pb-[1.5rem]\">\n<div class=\"h-full\">\n<div class=\"react-scroll-to-bottom--css-vruva-79elbk h-full\">\n<div class=\"react-scroll-to-bottom--css-vruva-1n7m0yu\">\n<div class=\"flex flex-col text-sm md:pb-9\">\n<article class=\"w-full text-token-text-primary focus-visible:outline-2 focus-visible:outline-offset-[-4px]\" dir=\"auto\" data-testid=\"conversation-turn-3\" data-scroll-anchor=\"true\">\n<div class=\"m-auto text-base py-[18px] px-6\">\n<div class=\"mx-auto flex flex-1 gap-4 text-base md:gap-5 lg:gap-6 md:max-w-3xl\">\n<div class=\"group\/conversation-turn relative flex w-full min-w-0 flex-col agent-turn @xs\/thread:px-0 @sm\/thread:px-1.5 @md\/thread:px-4\">\n<div class=\"flex-col gap-1 md:gap-3\">\n<div class=\"flex max-w-full flex-col flex-grow\">\n<div class=\"min-h-8 text-message flex w-full flex-col items-end gap-2 whitespace-normal break-words text-start [.text-message+&amp;]:mt-5\" dir=\"auto\" data-message-author-role=\"assistant\" data-message-id=\"e9d1c8ff-1168-46b9-a5fc-dd0b712ad791\" data-message-model-slug=\"gpt-4o-mini\">\n<div class=\"flex w-full flex-col gap-1 empty:hidden first:pt-[3px]\">\n<div class=\"markdown prose w-full break-words dark:prose-invert light\">\n<h2>Novo Nordisk A\/S (NVO)<\/h2>\n<p><a href=\"https:\/\/www.stocktargetadvisor.com\/stock\/USA\/NYE\/NVO\">Novo Nordisk A\/S<\/a> has firmly established itself as a leading player in the rapidly growing obesity drug market, and its latest financial performance reinforces its robust position, and labelled a &#8220;Top Pick&#8221; by <a href=\"https:\/\/www.stocktargetadvisor.com\/top-stocks\">Stock Target Advisor-AI&#8217;s<\/a> analysis. The company reported impressive 2024 earnings with a 26% increase in annual sales, reaching ~$40.56bn, alongside a 26% rise in operating profit to ~$17.91bn. A major driver of this growth was the success of its GLP-1 drugs, Ozempic and Wegovy, which together accounted for 61% of total sales. These drugs are highly effective in treating Type 2 diabetes and obesity, making them central to Novo Nordisk&#8217;s revenue growth.<\/p>\n<h3>Positive Factors<\/h3>\n<p>The company&#8217;s dominance in the GLP-1 space is particularly notable. Ozempic and Wegovy have proven to be game-changers in the weight-loss market, with clinical studies showing significant weight reduction results. This has led to a surge in demand, positioning Novo Nordisk to potentially lead a $150bn-per-year obesity treatment industry by 2030. Despite competition, including from Eli Lilly\u2019s tirzepatide, Novo\u2019s market share remains strong, and their innovations continue to fuel investor optimism.<\/p>\n<h3>Headwinds<\/h3>\n<p>However, despite this growth, there are some headwinds. The company is facing legal challenges, such as class-action lawsuits related to misleading statements about clinical outcomes, which has weighed on its stock price in the short term. Additionally, while the next-generation weight-loss drug CagriSema showed promising results, it fell short of expectations, leading to a slight dip in the stock price. This disappointment has slightly impacted investor sentiment, but it\u2019s important to note that management has plans for a 2026 approval submission, keeping optimism alive for future growth.<\/p>\n<h3>Growth Forecasts<\/h3>\n<p>Looking ahead, Novo Nordisk&#8217;s 2025 guidance projects continued growth, with sales expected to rise by 16-24% and operating profits by 19-27%. These estimates suggest that Novo could reach ~$49bn in revenue and ~$22bn in operating profit by mid-2025. Additionally, the company\u2019s planned 21% dividend increase, with an anticipated yield of 1.7%, adds to its appeal for investors seeking income and stability.<\/p>\n<h3>Analyst Consensus<\/h3>\n<p>Despite recent challenges, analysts continue to maintain a bullish outlook on Novo Nordisk. The stock is seen as underpriced on a cash-flow basis, providing an attractive entry point. With a &#8220;Strong Buy&#8221; rating and a target price of $150.04, analysts believe there is substantial upside potential, especially given that the stock closed at $82.62 recently. This suggests that the market has not fully priced in the company\u2019s strong growth prospects, particularly in the obesity treatment space.<\/p>\n<h3>Outlook<\/h3>\n<p>In conclusion, while there are some hurdles to navigate, Novo Nordisk\u2019s financial health, growth potential in the obesity drug market, and dominant position in the GLP-1 space continue to make it an attractive investment and a &#8220;Top Pick&#8221;, with the possibility of a 81 percent upside within the next 12 month period. The company is well-positioned for long-term success, and investors with a forward-looking perspective may find significant upside in its stock.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"mb-2 flex gap-3 empty:hidden -ml-2\">\n<div class=\"items-center justify-start rounded-xl p-1 flex\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"md:pt-0 dark:border-white\/20 md:border-transparent md:dark:border-transparent w-full isolate has-[[data-has-thread-error]]:[box-shadow:var(--sharp-edge-bottom-shadow)] has-[[data-has-thread-error]]:pt-2\">\n<div>\n<div class=\"m-auto text-base px-3 md:px-4 w-full md:px-5 lg:px-4 xl:px-5\">\n<div class=\"mx-auto flex flex-1 gap-4 text-base md:gap-5 lg:gap-6 md:max-w-3xl\">\n<form class=\"w-full\" aria-haspopup=\"dialog\" aria-expanded=\"false\" aria-controls=\"radix-:rq:\" data-state=\"closed\">\n<div class=\"relative z-[1] flex h-full max-w-full flex-1 flex-col\">\n<div class=\"group relative z-[1] flex w-full items-center\">\n<div class=\"w-full\">\n<div id=\"composer-background\" class=\"flex w-full cursor-text flex-col rounded-3xl border border-token-border-light px-3 py-1 transition-colors contain-inline-size dark:border-none dark:shadow-none shadow-[0_9px_9px_0px_rgba(0,0,0,0.01),_0_2px_5px_0px_rgba(0,0,0,0.06)] bg-token-main-surface-primary dark:bg-[#303030]\">\n<div class=\"flex min-h-[44px] items-start pl-1\">\n<div class=\"w-[32px] pt-1\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/form>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S (NVO) Novo Nordisk A\/S has firmly established itself as a leading player in the rapidly growing obesity drug market, and its latest&#8230;<\/p>\n","protected":false},"author":3,"featured_media":42624,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-61021","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-blog","post_format-post-format-image"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v19.4 (Yoast SEO v21.4) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted | Stock Target Advisor<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NVO) Novo Nordisk A\/S has firmly established itself as a leading player in the rapidly growing obesity drug market, and its latest...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/\" \/>\n<meta property=\"og:site_name\" content=\"Stock Target Advisor\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-06T04:37:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/11\/Novo-Nordisks-Wegovy-Data-Boosts-Stock-to-1-Month-High.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"STA Research\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:site\" content=\"@AdvisorTarget\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"STA Research\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/\"},\"author\":{\"name\":\"STA Research\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\"},\"headline\":\"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted\",\"datePublished\":\"2025-02-06T04:37:58+00:00\",\"dateModified\":\"2025-02-06T04:37:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/\"},\"wordCount\":490,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"articleSection\":[\"Market News &amp; Insights\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/\",\"name\":\"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted | Stock Target Advisor\",\"isPartOf\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\"},\"datePublished\":\"2025-02-06T04:37:58+00:00\",\"dateModified\":\"2025-02-06T04:37:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#website\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"name\":\"Stock Target Advisor\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#organization\",\"name\":\"Stock Target Advisor\",\"alternateName\":\"STA\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"contentUrl\":\"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg\",\"width\":\"225\",\"height\":\"225\",\"caption\":\"Stock Target Advisor\"},\"image\":{\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/StockTargetAdvisor\/\",\"https:\/\/twitter.com\/AdvisorTarget\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae\",\"name\":\"STA Research\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g\",\"caption\":\"STA Research\"},\"description\":\"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.\",\"url\":\"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted | Stock Target Advisor","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted","og_description":"Novo Nordisk A\/S (NVO) Novo Nordisk A\/S has firmly established itself as a leading player in the rapidly growing obesity drug market, and its latest...","og_url":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/","og_site_name":"Stock Target Advisor","article_publisher":"https:\/\/www.facebook.com\/StockTargetAdvisor\/","article_published_time":"2025-02-06T04:37:58+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-content\/uploads\/2023\/11\/Novo-Nordisks-Wegovy-Data-Boosts-Stock-to-1-Month-High.jpg","type":"image\/jpeg"}],"author":"STA Research","twitter_card":"summary_large_image","twitter_creator":"@AdvisorTarget","twitter_site":"@AdvisorTarget","twitter_misc":{"Written by":"STA Research","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/#article","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/"},"author":{"name":"STA Research","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae"},"headline":"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted","datePublished":"2025-02-06T04:37:58+00:00","dateModified":"2025-02-06T04:37:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/"},"wordCount":490,"commentCount":0,"publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"articleSection":["Market News &amp; Insights"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/","url":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/","name":"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted | Stock Target Advisor","isPartOf":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website"},"datePublished":"2025-02-06T04:37:58+00:00","dateModified":"2025-02-06T04:37:58+00:00","breadcrumb":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/novo-nordisk-a-s-ai-powered-top-stock-pick-with-81-percent-upside-forecasted\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.stocktargetadvisor.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk A\/S: AI-Powered Top Stock Pick with 81 Percent Upside Forecasted"}]},{"@type":"WebSite","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#website","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","name":"Stock Target Advisor","description":"","publisher":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.stocktargetadvisor.com\/blog\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#organization","name":"Stock Target Advisor","alternateName":"STA","url":"https:\/\/www.stocktargetadvisor.com\/blog\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/","url":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","contentUrl":"http:\/\/stocktargetadvisor.com\/wp-content\/uploads\/2019\/10\/STAlogo.jpeg","width":"225","height":"225","caption":"Stock Target Advisor"},"image":{"@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/StockTargetAdvisor\/","https:\/\/twitter.com\/AdvisorTarget"]},{"@type":"Person","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/e15ebb81d4f6861fcecbe1abc54e1cae","name":"STA Research","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.stocktargetadvisor.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/13a95c75b44f95ead23f47f0bf10667e57b44ec5150180c8a39a39361cf56169?s=96&d=mm&r=g","caption":"STA Research"},"description":"STA Research (StockTargetAdvisor.com) is a independent Investment Research company that specializes in stock forecasting and analysis with integrated AI, based on our platform stocktargetadvisor.com, EST 2007.","url":"https:\/\/www.stocktargetadvisor.com\/blog\/author\/sta-research\/"}]}},"_links":{"self":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/61021","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/comments?post=61021"}],"version-history":[{"count":3,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/61021\/revisions"}],"predecessor-version":[{"id":61025,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/posts\/61021\/revisions\/61025"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media\/42624"}],"wp:attachment":[{"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/media?parent=61021"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/categories?post=61021"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.stocktargetadvisor.com\/blog\/wp-json\/wp\/v2\/tags?post=61021"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}